AMD to Report Fiscal Second Quarter 2025 Financial Results GlobeNewswire July 08, 2025 SANTA CLARA, Calif., July 08, 2025 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) announced today that it will report fiscal second quarter 2025 financial results on Tuesday, Aug. 5, 2025, after the market close. Management will conduct a conference call to discuss these […]
Strategic alternatives, including a full sale of the business, must be pursued in order to unlock the full value of the platform. Believes Grove could be conservatively valued at ~0.70x – 0.90x 2025E revenue in such a transaction, which equates to a ~90 – 140% premium to the Company's current share price of $1.19 or
The law firm ofKessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc.(“Sarepta”) (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August
(NYSE:ELV), PHILADELPHIA, July 08, 2025 (GLOBE NEWSWIRE) — Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Elevance Health (NYSE: ELV) Investors to Inquire About a Securities Fraud Class Action by July 11, 2025 GlobeNewswire July 08, 2025 PHILADELPHIA, July 08, 2025 (GLOBE NEWSWIRE) — Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or
(Paris:GNFT), Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Credit Industriel et Commercial. Under the liquidity contract GENFIT has with
Kimberly-Clark (NASDAQ: KMB) will issue its second quarter 2025 results on Friday, August 1. A press release and supplemental materials will be issued at approximately 6:30 a.m. EDT. Kimberly-Clark management will then host a live Q&A session with analysts beginning at 8:00 a.m. EDT. The earnings release, supplemental materials, and Kimberly-Clark's Q&A session can be
Following a settlement hearing held on May 30, 2025 pursuant to the Mutual Fund Dealer Rules, a hearing panel of the Canadian Investment Regulatory Organization (CIRO) issued its reasons for decision, in the matter of David Alan Robertson, on June 23, 2025. The hearing panel's reasons for decision are available at: Re Robertson 2025 CIRO
Genfit: Half-Year Report of Liquidity Contract with Credit Industriel et Commercial GlobeNewswire July 08, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the
Messari report shows Starboard registered over 5 million community actions for 20 projects including Sui in its first month. https://mma.prnewswire.com/media/2727029/Galxe_Logo.jpg Leading crypto analyst Messari today reports that InfoFi platform Starboard from web3 growth leader Galxe has captured millions of engagements in just one month since its launch. Since launch, Starboard has indexed over 150,000 posts,